Sells placental grafts and other products for chronic and hard-to-heal wounds to hospitals, wound care clinics and physician offices; also sells tissue products for surgical applications.
10-K for FY2025, filed Feb 25, 2026Today, our product portfolio is routinely used to help clinicians treat patients suffering from chronic and other hard-to-heal wounds, in…View ↗
Our placental allografts are human tissues that are derived from one person (the donor) and used to process products that treat multiple…View ↗
Our product offering is comprised of tissue allografts derived from human placental membrane, umbilical cord, the placental disc, and, in…View ↗
Our direct sales team includes field sales representatives and field sales management, who call on hospitals, wound care clinics, physician…View ↗
Customers buy products by shipment or consignment; shipped orders are invoiced when shipped, while consigned products are billed when implanted or applied. Payment is typically due 30 to 60 days after ownership passes.
10-K for FY2025, filed Feb 25, 2026The Company sells its products primarily to individual customers and independent distributors (collectively referred to as “customers”).…View ↗
The Company recognizes revenue as performance obligations are fulfilled, which generally occurs upon the shipment of product to the…View ↗
The Company’s payment terms for customers are typically 30 to 60 days from receipt of title of the goods.View ↗
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by product or service ↗$418.6M
10-K for FY2025, filed Feb 25, 2026
$418.6M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Wound
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
66%
FY2022: 66%
|
Wound, FY2025
$276.3M Sources
|
Sold outright |
|
Surgical
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
34%
FY2022: 34%
|
Surgical, FY2025
$142.3M Sources
|
Sold outright |
MiMedx's direct sales team calls on hospitals and federal health care facilities, wound care clinics, and physician offices. Distributors buy products wholesale and resell them to providers and end users; independent sales agents cover some surgical applications and areas without a full-time representative.
10-K for FY2025, filed Feb 25, 2026
Yes. It kept 12 cents of every revenue dollar as net income in FY2025 and turned 17 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 28, 2026
−$8.7MView ↗
10-Q for Q3 FY2026, filed Oct 28, 2026
Open tableView ↗
8-K, filed Jul 29, 2026
For 2026, MIMEDX continues to expect 2026 net sales to be in a range of $260 to $290 million. 2026 Adjusted EBITDA is expected to approach…View ↗
Growing. Revenue grew 73% in 4 years, from $242M in FY2021 to $418.6M in FY2025, about 15% a year.
Broader product range
The earlier report centered its portfolio on placental allografts. The latest report describes an expanded offering that includes animal-derived collagen and wound products from third-party manufacturers and distribution partners.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 25, 2026Since its inception, MIMEDX has focused on leading the industry with its deep expertise, unmatched peer-reviewed scientific and clinical…View ↗
In 2024, we obtained the exclusive rights for and launched our first xenograft product and first U.S. Food & Drug Administration (“FDA”)…View ↗
In 2025 and early 2026, we entered into exclusive distribution agreements for several products, including:View ↗
RegenKit®-Wound Gel, an autologous platelet-rich plasma (“PRP”) and autologous thrombin serum (“ATS”) wound gel. NovaForm® Wound Matrix, a…View ↗
Competes with Integra LifeSciences Holdings, Organogenesis, and Smith & Nephew
10-K for FY2025, filed Feb 25, 2026Our main publicly-traded competitors in the skin substitute market include Integra LifeSciences Holdings Corporation, Organogenesis, Inc.…View ↗
Loading...